ASH 2019   |  December 11, 2019   Acalabrutinib Regimens Improve PFS in Treatment-Naïve Patients with CLL Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia. Read more   ADVERTISEMENT   Frontline Ibrutinib/Venetoclax Provides High Rates of Undetectable MRD in CLL First-line treatment with ibrutinib plus venetoclax provided high rates of undetectable minimal residual disease in peripheral blood and bone marrow of patients with chronic lymphocytic leukemia. Read more